



### Conference or Workshop Item

**Singer, Andrew**. 2010 How influenza pandemic control can lead to unpreparedness: modelling the ecotoxicity of pharmaceutical usage. [Other] In: *Influenza 2010: Zoonotic Influenza and Human Health, Oxford, UK, 21-23 September 2010*. (Unpublished)

This version available at <a href="http://nora.nerc.ac.uk/12268/">http://nora.nerc.ac.uk/12268/</a>

NERC has developed NORA to enable users to access research outputs wholly or partially funded by NERC. Copyright and other rights for material on this site are retained by the authors and/or other rights owners. Users should read the terms and conditions of use of this material at http://nora.nerc.ac.uk/policies.html#access

### Contact CEH NORA team at noraceh@ceh.ac.uk

The NERC and CEH trade marks and logos ('the Trademarks') are registered trademarks of NERC in the UK and other countries, and may not be used without the prior written consent of the Trademark owner.

NATURAL ENVIRONMENT RESEARCH COUNCI



## How influenza pandemic control can lead to unpreparedness: modelling the ecotoxicity of pharmaceutical usage

### Andrew Singer acsi@ceh.ac.uk

Centre for Ecology & Hydrology Wallingford, UK

## "Dilution is the Solution to Pollution"

- Many drugs are minimally metabolised in the body.
- As a general rule, if a drug persists in the body it will likely persist in the environment.
- Is there enough water available to dilute projected drug use during an influenza pandemic?
- If not, what's the potential impact?



CabinetOffice



### PANDEMIC FLU

January 2007 Vol 62 Supplement I

A national framewo responding to an in



Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic


Provisional guidelines from the British Infection Society, British Thoracic Society and Health Protection Agency in collaboration with the Department of Health What is Pandemic Preparedness?

... to slow the spread of influenza, through:


1) vaccines,

2) non-pharmaceutical measures


### 3) antivirals



## 1. epidemic model







### GLEaM – Global Epidemic and Mobility model

### air mobility layer

- f 3400 airports in 220 countries
- f 20,000 connections
- f traffic data (IATA, OAG)
- f >99% commercial traffic

### commuting mobility layer

- f daily commuting data
- f >30 countries in 5 continents
- f universal law of mobility

### demographic layer


f cells ¼° x ¼°
f tessellation around
transportation hubs




www.epiwork.eu

Balcan et al. PNAS (2009)


### Pharmaceutical Use Model During an Influenza Pandemic




 $R_0$  = number of secondary cases of influenza produced by 1 infected individual




Kaiser (2003) Arch Intern Med; Nicholson (2000) Lancet; Treanor (2000) JAMA; Whitley (2000) Pediatr Infect Dis J








## Baseline Antibiotic Use (excreted in England)




NHS BSA (2008) http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/NPC\_Antibiotics\_July\_2008.ppt


## results: antibiotics in WWTPs



## LF2000-WQX works



## **Determining Impact**



### toxicity (0-100%)

'Potentially affected fraction'


of sewage or river microbial

species




European Society of Clinical Microbiology and Infectious Diseases


### EUCAST MIC Distribution - Reference Database 2010-11-10




## Ecotoxicity: Species sensitivity distributions based on Minimum Inhibitory Concentrations



### results: toxicity in WWTPs



## Spatial distribution of toxicity in WWTPs & Rivers




% of Thames River length >5% PAF  $\leq 10$ 

**≤ 40** 

## **General Conclusions**

# Impact




### antiviral and antibiotics resistance

## Solutions ?

# VACCINATION!!

## **Priority Research**

## Pandemic usage of Pharmaceuticals



## <u>Thanks to Collaborators</u>...and you!

# Vittoria Colizza Heike Schmitt

## Alessandro Vespignani





Universiteit Utrecht Institute for Risk Assessment Sciences





### Virginie D. J. Keller **Richard J. Williams**

